½ÃÀ庸°í¼­
»óǰÄÚµå
1609619

¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ºÎÀ§º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, ¿¬·Éº°, Àα¸Åë°èº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

U.S. Blood Collection Market Size, Share & Trends Analysis Report By Site (Venous, Capillary), By Application (Diagnostics, Treatment), By End Use, By Age, By Demography, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 90 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 20¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀº 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 8.91%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¸¼ºÁúȯ ¹× °¨¿°¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ¼öÇ÷ Ƚ¼ö Áõ°¡, Ç÷¾× ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÁÖ·Î Àüü ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, CDC µ¥ÀÌÅÍ¿¡ µû¸£¸é 2022³â¿¡´Â ¾à 3,800¸¸ ¸íÀÇ ¼ºÀÎÀÌ ´ç´¢º´À» ¾Î°í ÀÖÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ºñ¸¸Àº ¸Å³â »õ·Î¿î Á¦ 2 Çü ´ç´¢º´ ȯÀÚÀÇ ÃÖ´ë 53 %¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù. µû¶ó¼­ ´ç´¢º´ À¯º´·üÀÇ Áõ°¡´Â Ç÷´ç ÃøÁ¤°ú °°Àº ¹Ýº¹ Áø´Ü °Ë»ç¿¡¼­ Áø°ø û¼Ò±â¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ç÷¾× ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÀÌ·¯ÇÑ ÁúȯÀ» Áø´ÜÇϱâ À§ÇÑ Áø°ø äÇ÷±âÀÇ Çʿ伺À» °­Á¶Çϸç Áø°ø äÇ÷±â¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹éÇ÷º´ ¹× ¸²ÇÁÁ¾ ÇùȸÀÇ º¸°í¿¡ µû¸£¸é, ¾à 3¸í Áß 1¸íÀÌ Ç÷¾×¾Ï Áø´ÜÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌó·³ Ç÷¾× ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Áø´Ü ¹× ¸ð´ÏÅ͸µÀ» À§ÇÑ È¿°úÀûÀΠäÇ÷ ¹æ¹ýÀÌ ÇÊ¿äÇϸç, À̴ äÇ÷ ½ÃÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀ¸·Î äÇ÷ ½ÃÀåÀº ´õ¿í °íµµÈ­µÇ°í Á¤È®µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾à±¹, ÀÀ±Þ¼¾ÅÍ, Áø·á¼Ò µî ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ POCT(Point-of-Care Testing) ¼Ö·ç¼ÇÀÇ È®´ë´Â ¹Ì±¹ ³» äÇ÷ ¼ö¿ä¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌó·³ Áö¿ª ¾à±¹µéÀº POCT¿¡¼­ ¿ªÇÒÀ» È®´ëÇϰí ÀÖÀ¸¸ç, ¹Ì±¹¿¡¼­´Â äÇ÷À» Æ÷ÇÔÇÑ Æí¸®Çϰí Á¢±ÙÇϱ⠽¬¿î Áø´Ü ¼­ºñ½º¸¦ ȯÀڵ鿡°Ô Á÷Á¢ Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ºÎÀ§º°·Î´Â Á¤¸Æ ºÎ¹®ÀÌ 82.44%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ±× ÀÌÀ¯´Â °íǰÁú »ùÇÃÀ» ¾òÀ» ¼ö ÀÖ´Â ½Å·Ú¼º°ú È¿À²¼º ¶§¹®ÀÎ °ÍÀ¸·Î ºÐ¼®µË´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ºÎ¹®ÀÌ 28.01%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇϰí ÀÖ½À´Ï´Ù.
  • ¿¬·Éº°·Î´Â 19-65¼¼ ºÎ¹®ÀÌ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • µµ½Ã ºÎ¹®Àº 2024³â ¹Ì±¹ ½ÃÀåÀ» Àå¾ÇÇÏ°í ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå º¯µ¿ µ¿Çâ°ú ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå
    • º¸Á¶ ½ÃÀå
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
    • ½ÃÀå ±âȸ ºÐ¼®
    • ½ÃÀå °úÁ¦ ºÐ¼®
  • ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
    • °¡°Ý ºÐ¼®
    • µ¿¹° ÃßÁ¤ °³Ã¼¼ö, ÁÖ¿ä ±¹°¡º°¡¤ÁÖ¿ä Á¾º°, 2024³â
    • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå : ºÎÀ§ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå : ºÎÀ§ º¯µ¿ ºÐ¼®
  • ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ºÎÀ§º°, 2018-2030³â
  • Á¤¸Æ
  • ¸ð¼¼Ç÷°ü
    • ¶õ¼Â
    • ¸¶ÀÌÅ©·Î ÄÁÅ×ÀÌ³Ê Æ©ºê
    • ¸¶ÀÌÅ©·Î Ç츶ÅäÅ©¸®Æ® Æ©ºê
    • °¡¿Â Àåºñ
    • ±âŸ

Á¦5Àå ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå : ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå : ¿ëµµº° º¯µ¿ ºÐ¼®
  • ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¿ëµµº°, 2018-2030³â
  • Áø´Ü
  • Ä¡·á

Á¦6Àå ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå : ÃÖÁ¾ ¿ëµµº° º¯µ¿ ºÐ¼®
  • ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
  • º´¿ø
  • ÀÓ»ó °Ë»ç½Ç
  • Ç÷¾×ÀºÇà ¼¾ÅÍ
  • Ŭ¸®´Ð
  • ¸ð¹ÙÀÏ ¼­ºñ½º
  • ±¸±Þ°ú
  • ±âŸ

Á¦7Àå ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå : ¿¬·Éº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå : ¿¬·Éº° º¯µ¿ ºÐ¼®
  • ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¿¬·Éº°, 2018-2030³â
    • 0-18¼¼
    • 19-65¼¼
    • 66¼¼ ÀÌ»ó

Á¦8Àå ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå : Àα¸Åë°èº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå : Àα¸Åë°èº° º¯µ¿ ºÐ¼®
  • ¹Ì±¹ÀÇ Ã¤Ç÷ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Àα¸Åë°èº°, 2018-2030³â
    • µµ½Ã
    • ½Ã°ñ

Á¦9Àå °æÀï ±¸µµ

  • ½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
  • ±â¾÷ ½ÃÀå »óȲ ºÐ¼®/heap ¸Ê ºÐ¼®
  • ±â¾÷ °³¿ä
    • Sekisui Medical Co., Ltd.
    • Becton, Dickinson and Company(BD)
    • Greiner Bio-One
    • QIAGEN
    • Nipro Corporation
    • Terumo Corporation
    • Haemonetics Corp.
    • Zhejiang Gongdong Medical Technology Co., Ltd
    • Drucker Diagnostics
    • AdvaCare Pharma
  • Àü·« ¸ÅÇÎ
    • ÀμöÇÕº´
    • ÆÄÆ®³Ê½Ê°ú Çù¾÷
    • È®´ë
    • Á¦Ç° ¹ß¸Å
    • ±âŸ
  • ±âŸ ÁÖ¿ä ±â¾÷ ¸®½ºÆ®
ksm 24.12.26

U.S. Blood Collection Market Growth & Trends:

The U.S. blood collection market size is expected to reach USD 2.08 billion by 2030, according to a new study by Grand View Research, Inc. The market is projected to grow at a CAGR of 8.91% from 2025 to 2030. The increasing prevalence of chronic and infectious diseases, growing number of blood transfusions, and rising prevalence of hematological disorders are primarily driving the overall market growth. As per CDC data, approximately 38 million adults were suffering from diabetes in 2022. In addition, obesity is linked to up to 53% of new type 2 diabetes cases annually. Thus, the increasing prevalence of diabetes is expected to boost the demand for vacutainers in recurring diagnostic tests, such as blood sugar assays.

The growing prevalence of hematological disorders highlights the need for vacutainers to diagnose these disorders, driving the demand for vacuum blood collection devices. For instance, the Leukemia & Lymphoma Society reports that approximately one person is diagnosed with blood cancer every 3 minutes. This increasing burden of hematological disorders necessitates effective blood collection methods for diagnosis and monitoring, thereby propelling the blood collection market.

The growing advancements in technology have made the blood collection market more sophisticated and accurate. Moreover, expansion of Point-of-Care Testing (POCT) solutions in various healthcare settings, including pharmacies, urgent care centers, and clinics, can drive the demand for blood collection in the U.S. Community pharmacies are increasingly playing a pivotal role in collection services, leveraging their accessibility and patient trust to enhance healthcare delivery. Thus, community pharmacies are expanding their role in POCT, offering convenient and accessible diagnostic services, including blood collection, directly to patients in the U.S.

U.S. Blood Collection Market Report Highlights:

  • Based on site, the venous segment dominated the market with a revenue share of 82.44%. owing to its reliability and efficiency in obtaining high-quality samples.
  • Based on end use, the hospitals segment dominated the market with a revenue share of 28.01%, owing to the high number of cases and diagnostic tests being conducted.
  • Based on age, the 19 to 65 segments accounted for the largest market share in 2024 and are expected to grow at the fastest CAGR over the forecast period
  • The urban segment dominated the U.S. market in 2024 and is expected to grow at the fastest CAGR over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Country Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Blood Collection Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Prevalence of Chronic and Infectious Diseases
      • 3.2.1.2. Growing Number of Blood Transfusions
      • 3.2.1.3. Rising Prevalence of Hematological Disorders
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Risks Associated with Blood Collection
      • 3.2.2.2. Stringent Regulations on Blood Collection
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Blood Collection Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework
    • 3.3.4. Pricing Analysis
    • 3.3.5. Estimated Animal Population, by key countries & Key species, 2024
    • 3.3.6. COVID-19 Impact Analysis

Chapter 4. U.S. Blood Collection Market: Site Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Blood Collection Market: Site Movement Analysis
  • 4.3. U.S. Blood Collection Market Size & Trend Analysis, by Site, 2018 to 2030 (USD Million) (Volume, Units Sold in Million)
  • 4.4. Venous
    • 4.4.1. Venous Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)
      • 4.4.1.1. Needles and Syringes
        • 4.4.1.1.1. Double-Ended Needles
        • 4.4.1.1.2. Winged Blood Collection Sets
        • 4.4.1.1.3. Standard Hypodermic Needles
        • 4.4.1.1.4. Other Blood Collection Needles
      • 4.4.1.2. Blood Collection Tubes
        • 4.4.1.2.1. Serum-separating tubes
        • 4.4.1.2.2. EDTA
        • 4.4.1.2.3. Heparin
        • 4.4.1.2.4. Plasma-separating
      • 4.4.1.3. Blood Bags
      • 4.4.1.4. Others
  • 4.5. Capillary
    • 4.5.1. Capillary Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)
    • 4.5.2. Lancets
    • 4.5.3. Micro-Container Tubes
    • 4.5.4. Micro-Hematocrit Tubes
    • 4.5.5. Warming Devices
    • 4.5.6. Others

Chapter 5. U.S. Blood Collection Market: By Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Blood Collection Market: By Application Movement Analysis
  • 5.3. U.S. Blood Collection Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million) (Volume, Units Sold in Million)
  • 5.4. Diagnostics
    • 5.4.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)
  • 5.5. Treatment
    • 5.5.1. Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)

Chapter 6. U.S. Blood Collection Market: By End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Blood Collection Market: By End Use Movement Analysis
  • 6.3. U.S. Blood Collection Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million) (Volume, Units Sold in Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)
  • 6.5. Clinical Laboratories
    • 6.5.1. Clinical Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)
  • 6.6. Blood Banks Centers
    • 6.6.1. Blood Banks Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)
  • 6.7. Clinics
    • 6.7.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)
  • 6.8. Mobile Service
    • 6.8.1. Mobile Service Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)
  • 6.9. Emergency Departments
    • 6.9.1. Emergency Departments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)
  • 6.10. , Others
    • 6.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)

Chapter 7. U.S. Blood Collection Market: By Age Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Blood Collection Market: By Age Movement Analysis
  • 7.3. U.S. Blood Collection Market Size & Trend Analysis, by Age, 2018 to 2030 (USD Million) (Volume, Units Sold in Million)
    • 7.3.1. 0-18
      • 7.3.1.1. 0-18 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)
    • 7.3.2. 19 to 65
      • 7.3.2.1. 19 to 65 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)
    • 7.3.3. 66 years and above
      • 7.3.3.1. 66 years and Above Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)

Chapter 8. U.S. Blood Collection Market: By Demography Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. U.S. Blood Collection Market: By Demographic Movement Analysis
  • 8.3. U.S. Blood Collection Market Size & Trend Analysis, by Demographic, 2018 to 2030 (USD Million) (Volume, Units Sold in Million)
    • 8.3.1. Urban
      • 8.3.1.1. Urban Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)
    • 8.3.2. Rural
      • 8.3.2.1. Rural Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) (Volume, Units Sold in Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Position Analysis/ Heap Map Analysis
  • 9.3. Company Profiles
    • 9.3.1. Sekisui Medical Co., Ltd.
      • 9.3.1.1. Company overview
      • 9.3.1.2. Financial performance
      • 9.3.1.3. Product benchmarking
      • 9.3.1.4. Strategic initiatives
    • 9.3.2. Becton, Dickinson and Company (BD)
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Product benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Greiner Bio-One
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. QIAGEN
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Nipro Corporation
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Terumo Corporation
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Haemonetics Corp.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Zhejiang Gongdong Medical Technology Co., Ltd
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Drucker Diagnostics
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. AdvaCare Pharma
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
  • 9.4. Strategy Mapping
    • 9.4.1. Mergers & Acquisitions
    • 9.4.2. Partnerships & Collaborations
    • 9.4.3. Expansion
    • 9.4.4. Product launch
    • 9.4.5. Others
  • 9.5. List of other Key players
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦